CoChat

Clinical relevance of anti‐exenatide antibodies: safety, efficacy and cross‐reactivity with long‐term treatment

Fineman, M. S., Mace, K. F., Diamant, M., Darsow, T., Cirincione, B. B., Booker Porter, T. K., Kinninger, L. A., Trautmann, M. E. · 2012 · Diabetes, Obesity and Metabolism
Cited by 152

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Aims: Antibody formation to therapeutic peptides is common. This analysis characterizes the time‐course and cross‐reactivity of anti‐exenatide antibodies and potential effects on efficacy and safety. Methods: Data from intent‐to‐treat patients in 12 controlled (n = 2225,12–52weeks) and 5 uncontrolled (n = 1538, up to 3 years) exenatide twice‐daily (BID) trials and 4 controlled (n = 653,24–30weeks) exenatide once weekly (QW) trials with 1 uncontrolled period (n = 128,52weeks) were analysed. Results: Mean titres peaked early (6–22 weeks) and subsequently declined. At 30 weeks, 36.7% of exenatide BID patients were antibody‐positive; 31.7% exhibited low titres (≤125) and 5.0% had higher titres (≥625). Antibody incidence declined to 16.9% (1.4% higher titre) at 3 years. Similarly, 56.8% of exenatide QW patients were antibody‐positive (45.0% low/11.8% higher titre) at 24–30 weeks, declining to 45.4% positive (9.2% higher titre) at 52 weeks. Treatment‐emergent anti‐exenatide antibodies from a subset of patients tested did not cross‐react with human GLP‐1 or glucagon. Other than injection‐site reactions, adverse event rates in antibody‐positive and antibody‐negative patients were similar. Efficacy was robust in both antibody‐negative and antibody‐positive patients (mean HbA1c change: −1.0 and −0.9%, respectively, exenatide BID; −1.6% and −1.3% exenatide QW). No correlation between change in HbA1c and titre was observed for exenatide BID, although mean reductions were attenuated in the small subset of patients (5%) with higher titres. A significant correlation was observed for exenatide QW with no difference between antibody‐negative and low‐titre patients, but an attenuated mean reduction in the subset of patients (12%) with higher titres. Conclusions: Low‐titre anti‐exenatide antibodies were common with exenatide treatment (32% exenatide BID, 45% exenatide QW patients), but had no apparent effect on efficacy. Higher‐titre antibodies were less common (5% exenatide BID, 12% exenatide QW) and within that titre group, increasing antibody titre was associated with reduced average efficacy that was statistically significant for exenatide QW. Other than injection‐site reactions, anti‐exenatide antibodies did not impact the safety of exenatide.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2012.01561.x

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 152

Metadata

Authors
Fineman, M. S., Mace, K. F., Diamant, M., Darsow, T., Cirincione, B. B., Booker Porter, T. K., Kinninger, L. A., & Trautmann, M. E.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2012-02-10
Volume
14
Issue
6
Pages
546-554
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2009288620
Cited by
152
References
11
FWCI
11.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical relevance of anti‐exenatide antibodies: safety, efficacy and cross‐reactivity with long‐term treatment. https://app.cochat.ai/papers/10.1111/j.1463-1326.2012.01561.x
The paper
Fineman, M. S., Mace, K. F., Diamant, M., Darsow, T., Cirincione, B. B., Booker Porter, T. K., Kinninger, L. A., & Trautmann, M. E. (2012). Clinical relevance of anti‐exenatide antibodies: safety, efficacy and cross‐reactivity with long‐term treatment. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2012.01561.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.